WHAT IS CLAIMED IS:

1. A compound selected from 2-(l-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one and pharmaceutically acceptable salts thereof.

2. A compound selected from (S)-2-(l-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one and pharmaceutically acceptable salts thereof.

3. The compound according to claim 2, wherein the compound is substantially free of (R)-2-(l-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one, and pharmaceutical acceptable salts thereof.

4. The compound of claim 2, wherein the compound has an enantiomeric excess greater than about 95%.

5. (S)-2-(l-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one.

6. The compound of claim 5, wherein the compound is substantially free of (R)-2-(l-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one.

7. The compound of claim 5, wherein the compound has an enantiomeric excess greater than about 95%.

8. A pharmaceutical composition comprising a compound according to any one of claims 1-7 and at least one pharmaceutically acceptable carrier.

9. A method of inhibiting a catalytic activity of a PI3 δ kinase present in a cell, comprising contacting the cell with an effective amount of a compound according to any one of claims 1-7.

10. A method of inhibiting a catalytic activity of a PI3 γ kinase present in a cell, comprising contacting the cell with an effective amount of a compound according to any one of claims 1-7.

11. A method of inhibiting a catalytic activity of a PI3 δ kinase and PI3 γ kinase present in a cell, comprising contacting the cell with an effective amount of a compound according to any one of claims 1-7.

12. The method of any one of claims 9-11, wherein the inhibition takes place in a subject suffering from a disease, disorder or condition selected from cancer, a bone disorder, an inflammatory disease, an immune disease, a nervous system disease, a metabolic disease, a respiratory disease, thrombosis, and cardiac disease.

13. Use of a compound of any one of claims 1-7, in the manufacture of a medicament for the treatment of a disease, disorder or condition that would benefit from inhibiting catalytic activity of a PI3 δ /γ kinase.

CLAIMS

1. A compound selected from 2-(l-(9H-purin-6-ylamino)propyl)-3-(3- fluorophenyl)-4H-chromen-4-one and pharmaceutically acceptable salts thereof.

2. A compound selected from (S)-2-(l-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one and pharmaceutically acceptable salts thereof.

3. The compound according to claim 2, wherein the compound is substantially free of (R)-2-(l-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one, and pharmaceutical acceptable salts thereof.

4. The compound of claim 2, wherein the compound has an enantiomeric excess greater than about 95%.

5. (S)-2-(I-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one.

6. The compound of claim 5, wherein the compound is substantially free of (R)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one.

7. The compound of claim 5, wherein the compound has an enantiomeric excess greater than about 95%.

8. A pharmaceutical composition comprising a compound according to any one of claims 1-7 and at least one pharmaceutically acceptable carrier.

9. An in vitro method of inhibiting a catalytic activity of a PI3 δ kinase present in a cell, comprising contacting the cell with an effective amount of a compound according to any one of claims 1-7.

10. An in vitro method of inhibiting a catalytic activity of a PI3 γ kinase

present in a cell, comprising contacting the cell with an effective amount of a compound according to any one of claims 1-7.

11. An in vitro method of inhibiting a catalytic activity of a PI3 δ kinase and PI3 γ kinase present in a cell, comprising contacting the cell with an effective amount of a compound according to any one of claims 1-7.

12. Use of a compound of any one of claims 1-7 in the manufacture of a medicament for the treatment of lymphoma.